InVentiv Health provides services to biotech and pharma companies acrss the spectrum of clinical development and commercialization.

Support Group International

Support Group International (SGI) delivers full-spectrum support services and products globally, specializing in solutions to complex requirements for governmental, commercial, and non-government organizations. Focus is on security, logistics, and medical support. SGI combines the capabilities and capacity of several supporting companies with extensive international experience, leadership, and unique products for their clients.

Sapience Therapeutics is a development stage biotechnology company focused on developing its lead compound, an activating transcription Factor 5 inhibitor. Sapience licensed the technology from Columbia University and its initial program targets glioblastoma.

Asepticys is a development stage company focused on developing new generation chemically-unique medical disinfection/sterilization solutions effective against a broad spectrum of microbial pathogens that are clinically beneficial in a number of medical and consumer healthcare applications.

The Medicines Company (NASDAQ:MDCO) is developing innovative drugs in the areas of infectious disease, anesthia, and lipids.

Carbon3D, a Silicon Valley based company, was founded in 2013 in Chapel Hill, NC. Working at the intersection of hardware, software and molecular science, Carbon3D is delivering on the promise of 3D printing, allowing commercial customers to go beyond basic prototyping to achieve 3D manufacturing.

A spinout from Duke University, developing immunotherapies for autoimmunity, cancer and immunodeficiency.

Innocrin Pharmaceutical Inc., a clinical stage company developing a lead small molecule which is both a CYP17 lyase-selective inhibitor and an androgen inhibitor to treat resistant hormonally-dependent breast and prostate cancers.

Developing "on demand" pharmaceuticals to restore voluntary control of bladder and bowel for people with spinal cord injury and neurological conditions.

Clinical-stage company developing small molecule therapies in the CDK4/6 & SERD categories to address significant unmet needs in oncology.

An operating private equity fund that in-licenses drug candidates and develops through late-stage for ultimate sale to a commercializing company.

A clinical stage company developing opthalmic products in a novel delivery device.

An early stage company providing healthcare information to children/families using "super hero" comic formats.

A spinout from UNC, researching and developing novel cancer treatments, including MER Kinase inhibitors.

Provides professional, medically outfitted emergency airlift from Caribbean to US medical centers.